Hospital Santa Caterina Ias

Salt 12 trials 4 recruiting

12 Registered trials

4 Currently recruiting

Organisation

Hospital Santa Caterina Ias

Location

Salt, Spain

Identifier

ORG-100050657

Address

Calle Del Doctor Castany S/N, 17190, Spain

Departments

#2304:servicio de neurología
#2413: Neurología
#5410 :neurologia
1311: Neurology
Dermatology
Neurology
Obstetrics and gynecology
Servicio de Neurologia

Clinical trials at this site (12)

Search interface

A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending

2025-524322-18-00 Non-active Secondary Progressive Multiple Sclerosis (SP 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2026-06-11
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-0… Recruiting

2025-523058-16-00 Skin Toxicities Associated with Epidermal Growth Factor 4 2026-04-28
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o… Recruiting

2023-509275-17-00 Relapsing multiple sclerosis 5 2025-10-06
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
A prospective, multicentre open-label clinical trial to evaluate the efficacy of the fixed-dose combination of Doxylamine and Pyridoxine 10/… Ended

2023-505144-19-00 Nausea and vomiting of pregnancy 6 2023-10-31
Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended

2023-507431-37-00 relapsing multiple sclerosis (RMS) 5 2021-07-23
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended

2024-514495-41-00 Primary Progressive Multiple Sclerosis 5 2020-11-04